Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 351 in Duchenne Muscular Dystrophy
NCT06280209Phase 2Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Apr 2027
- Modality
- Gene Editing, Gene Silencing, Modified DNA Oligonucleotides
- Countries
- 5
01
Overview
A Phase 2 trial of BMN-351 in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Started Jan 2024; status: active, not recruiting.
02
Drugs
BMN-351
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06280209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280209.